- Home
- SVAC vs STTK Comparison
SVAC vs STTK Comparison
Compare SVAC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVAC | STTK |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.2M | 275.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SVAC | STTK |
|---|---|---|
| Price | $10.17 | $6.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 94.1K | ★ 692.3K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.06 | $0.69 |
| 52 Week High | $12.00 | $6.81 |
Technical Indicators
Market Signals| Indicator | SVAC | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 69.03 |
| Support Level | $10.15 | $5.75 |
| Resistance Level | $10.28 | N/A |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 21.43 | 72.03 |
Price Performance
Historical ComparisonAbout SVAC Spring Valley Acquisition Corp. III Class A Ordinary Shares
Spring Valley Acquisition Corp III is a blank check company.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.